N@N

Michael Lapides Maintained (TSHA) at Hold with Decreased Target to $1 on, Mar 30th, 2023

^{Published on 2024-10-28 02:30:44 - WOPRAI, Michael Lapides}
 

Michael Lapides of Morgan Stanley, Maintained "Taysha Gene Therapies, Inc." (TSHA) at Hold with Decreased Target from $3 to $1 on, Mar 30th, 2023.

Michael has made no other calls on TSHA in the last 4 months.

There are 8 other peers that have a rating on TSHA. Out of the 8 peers that are also analyzing TSHA, 3 agree with Michael's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Yun Zhong of "BTIG" Downgraded from Strong Buy to Hold on, Thursday, February 2nd, 2023
• Eun Yang of "Jefferies" Downgraded from Strong Buy to Hold and Decreased Target to $1.5 on, Wednesday, February 1st, 2023
• Michael Ulz of "Morgan Stanley" Downgraded from Buy to Hold and Held Target at $3 on, Friday, January 27th, 2023

These are the ratings of the 5 analyists that currently disagree with Michael

---

• Gil Blum of "Needham" Reiterated at Strong Buy and Held Target at $6 on, Wednesday, March 29th, 2023
• Joon Lee of "Truist Securities" Maintained at Strong Buy with Decreased Target to $3 on, Wednesday, March 29th, 2023
• Whitney Ijem of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $13 on, Wednesday, February 1st, 2023
• Jack Allen of "Baird" Maintained at Buy with Decreased Target to $6 on, Wednesday, February 1st, 2023
• Yanan Zhu of "Wells Fargo" Maintained at Buy with Decreased Target to $10 on, Wednesday, January 4th, 2023

Contributing Sources

---